NEW YORK - Tiziana Life Sciences Ltd. (NASDAQ:TLSA), a biotechnology firm with a market capitalization of $165 million and an impressive 136% return over the past year, announced a significant reduction in neuroinflammation in an Alzheimer’s patient treated with its lead candidate, intranasal foralumab. The patient, part of an expanded access program, showed marked improvement in a PET scan after three months of treatment. According to InvestingPro analysis, the company’s stock is currently trading above its Fair Value, reflecting investor optimism about its pipeline potential.
The PET scan, conducted using a microglial TSPO PET scan, indicated a substantial decrease in microglial activation, which is closely linked to the progression of Alzheimer’s disease. These results were presented at the 2025 AD/PD Conference in Vienna and featured in the AlzForum, with the full report to be published in Clinical Nuclear Medicine.
Dr. Howard Weiner, Co-director of the Ann Romney Center for Neurologic Diseases, highlighted the drop in TSPO signal as highly encouraging, noting the absence of side effects and continued treatment for the patient. Dr. Tarun Singhal, Director of the PET Imaging Program in Neurologic Diseases, also remarked on the measurable reduction in microglial activation, calling for further studies in moderate Alzheimer’s disease.
Intranasal foralumab, a fully human anti-CD3 monoclonal antibody, has been shown to induce T regulatory cells that can travel to the brain and reduce neuroinflammation. This mechanism has been confirmed in animal models and subjects with secondary progressive multiple sclerosis (MS).
Tiziana’s CEO, Dr. Ivor Elrifi, expressed the critical nature of these findings for the company, emphasizing foralumab’s potential as a standalone treatment and in combination therapies for Alzheimer’s disease. Executive Chairman Gabriele Cerrone also commented on the consistent reduction of microglia activation seen in ongoing studies with secondary progressive MS patients.
With over 50 million people affected by Alzheimer’s globally and numbers expected to triple by 2050, the development of effective treatments, particularly for moderate stages of the disease, is urgent.
Foralumab is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis, and Tiziana’s innovative nasal delivery approach is patented with several applications pending. While the company reported negative EBITDA of $15.8 million in the last twelve months, InvestingPro data shows it maintains a moderate debt level and healthy current ratio of 1.02, providing financial flexibility for its ongoing research programs.
This news is based on a press release statement from Tiziana Life Sciences Ltd. For deeper insights into Tiziana’s financial health and growth prospects, InvestingPro subscribers have access to over 10 additional ProTips and comprehensive financial metrics, essential for understanding the investment potential in emerging biotech companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.